Anthropic is building a biology lab in the San Francisco area where its Claude model will guide robots through drug experiments with minimal human involvement, Reuters reported. The lab builds on Anth…
Anthropic's planned initial public offering, which could value the Claude maker at up to $2 trillion, will leave its experimental Long-Term Benefit Trust (LTBT) in control of the majority of its board…
Novartis CEO Vas Narasimhan said AI is helping speed up drug discovery timelines, as the pharma giant reported second-quarter earnings that topped estimates. Novartis stock rose Tuesday after the earn…
Anthropic launched its own drug discovery programs targeting neglected diseases that Big Pharma deems unprofitable. Novartis CEO Vas Narasimhan noted AI could cut development time from twelve to seven…